Key Takeaways LLY's Mounjaro and Zepbound generated $36.5B in 2025, about 56% of total revenuesLilly's duo leads U.S. diabetes and obesity new scripts, topping Novo Nordisk's semaglutide drugs.LLY plans to launch its oral GLP-1 orforglipron in the United States in 2026.Eli Lilly’s (LLY) key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite being on the market for slightly more than three years, Mounjaro and Zepbound have seen exceptional sales growth, ...

Ironwood Pharmaceuticals (NasdaqGS:IRWD) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Company ParticipantsAmy Li - SVP of Equity ResearchGregory Martini - SVP and CFOMichael Shetzline - Chief Medical OfficerTammi Gaskins - Chief Commercial OfficerThomas McCourt - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research AnalystDominic Rose - Equity Research AnalystJason Butler - Managing Director and Senior Biotechnology Equity Research AnalystMohit Bansal - Managing Director and Se ...

Ironwood Pharmaceuticals (NasdaqGS:IRWD) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Speaker6Thank you for standing by. My name is Liz, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q4 and Full Year 2025 Investor Update Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this ...

Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s common sto ...

Novo Nordisk A/S (NYSE:NVO) shares are down during Wednesday’s premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, adding pressure as broader markets edged lower.Novo Nordisk Announces Major GLP-1 Drug Price CutsThe price reduction, announced on Tuesday, will affect popular medications such as Wegovy, Ozempic, and Rybelsus, with the new list price set at $675 per month, down from current prices ranging fro ...

Alkermes (NasdaqGS:ALKS) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAmi Fadia - Managing DirectorAnya John - Research AssociateBlair Jackson - COODavid Huang - DirectorDouglas Tsao - Managing DirectorJason Gerberry - Managing DirectorJoon Lee - Managing DirectorJoseph Thome - Managing DirectorJoshua Reed - CFOJulian Pino - Biotechnology Equity ResearchRichard Pops - CEORudy Li - DirectorSandy Coombs - SVP of Investor Relations and Corporate AffairsTodd Nichols - Chief Commercial ...

Amarin Corporation (NasdaqCM:AMRN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAaron Berg - President and CEODevin Sullivan - VP of Investor RelationsPeter Fishman - CFOConference Call ParticipantsNone - AnalystNone - AnalystOperatorPlease note this conference is being recorded. I would now like to turn the conference call over to Devin Sullivan, Investor Relations for Amarin.Devin SullivanThank you for your time and attention this morning as we discuss Amarin's 2025 fourth quart ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBen Taylor - CFO and President of Recursion UKDave Hallett - Chief Scientific OfficerNajat Khan - CEO and PresidentNajat KhanGood morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of l ...

Amarin Corporation (NasdaqCM:AMRN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker2Please note this conference is being recorded. I would now like to turn the conference call over to Devin Sullivan, Investor Relations for Amarin.Speaker1Thank you for your time and attention this morning as we discuss Amarin's 2025 fourth quarter and full year financial results. On the call today are Aaron Berg, President and Chief Executive Officer, and Peter Fishman, Chief Financial Officer. Other members of th ...

Alkermes (NasdaqGS:ALKS) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker12Greetings, and welcome to the Alkermes' fourth quarter 2025 financial results conference call. My name is Melissa, and I will be your operator for today's call. All participant lines will be placed on mute to prevent background noise. If you should require operator assistance during the call, please press star 0 on your telephone keypad. Please note that this conference is being recorded. I will now turn the call over to S ...